Company Encyclopedia
View More
name
Vertex Pharma
VRTX.US
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics.
1.946 T
VRTX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking6/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE22.31%A
    • Profit Margin31.35%A
    • Gross Margin54.74%B
  • Growth ScoreB
    • Revenue YoY10.33%B
    • Net Profit YoY865.96%A
    • Total Assets YoY11.79%B
    • Net Assets YoY10.80%B
  • Cash ScoreC
    • Cash Flow Margin318.99%C
    • OCF YoY10.33%B
  • Operating ScoreC
    • Turnover0.5C
  • Debt ScoreB
    • Gearing Ratio30.34%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | Vertex Pharma sees increased volume and consecutive gains, is a short-term opportunity brewing in the innovative drug sector?

    Vertex Pharma opened strong this week, with significant movements in main funds, showing a clear increase in volume early on to support the price. Short-term market speculation enthusiasm surged. Some in the community shouted, "Large funds are gathering, is the innovative drug about to take off?" Throughout the day, there were multiple attempts to test upward movements, and the overall pace of the sector accelerated, boosting all pharmaceutical growth targets. Recently, the FDA's favorable news has just passed, making innovative drugs for rare diseases the focus, with progress on leading products and new indications continuously stimulating community funds to follow suit in speculation. There have been no major negative news at high levels recently; instead, some analysts have upgraded their ratings, leading to noticeable effects in the rush for several mainline innovative drugs. The "FOMO sentiment" has surged to new highs amid sector rotation. On the technical side, MACD/KDJ indicators have turned upward consecutively, and the main funds' protective actions have directly lifted the bottom. The warming of growth stocks + the return of funds have created a stage for pharmaceuticals, igniting speculative sentiment during the day. However, it is important to note that the RSI is approaching extreme high levels, and the Bollinger Bands are contracting, making it easy for significant divergences to occur in the short term, with severe internal high-low switches. The community's view is that the core track still has strong expectations, but the risks brought by high-level speculation are also magnified. Short-term chasing highs must closely monitor the volume—if the high-level volume does not follow and intraday movements accelerate, it is a signal for the main funds to cash out. With sector rotation, the market may take a breather, potentially dropping back to lower levels at any time. Therefore, trading at this stage is more suitable for quick in-and-out strategies; those who act quickly can profit, while hesitation may leave only the soup. The innovative drug sector's intraday movements have become the "leader," and once the signal for a trend change appears, it presents the biggest short-term opportunity

    Technical Forecast·
    US
    VRTX
    -1.25%
    Technical Forecast·
    US
    VRTX
    -1.25%

    Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

    Vertex Pharmaceuticals (VRTX) stock rose 6.2% after Morgan Stanley upgraded its rating to "Overweight" with a new price target of $516, up from $438. This optimism is driven by the potential of Vertex's kidney drug pipeline, specifically Pove and Inaxaplin, ahead of their Phase 3 clinical trial data release in 2026. The stock's performance also reflects broader market sentiment, including hopes for interest rate cuts.

    TradingView·
    US
    VRTX
    -1.25%
    TradingView·
    US
    VRTX
    -1.25%

    VP Biller Files To Sell 347 Of Vertex Pharmaceuticals Inc [VRTX]

    Jonathan Biller, VP of Vertex Pharmaceuticals, filed a Form 144 with the SEC to sell 347 shares of VRTX on December 3, 2025, under a prearranged trading plan (10b5-1).

    Reuters·
    US
    VRTX
    -1.25%
    Reuters·
    US
    VRTX
    -1.25%

    Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq?

    This article examines whether Vertex Pharmaceuticals (VRTX) is underperforming the Nasdaq, noting its significant year-to-date return of 33.64% compared to the Nasdaq's 34.62%. It highlights Vertex's strong performance indicators, including robust revenue growth and a high-profit margin, and discusses investor sentiment and future outlook. The analysis suggests that while it slightly lags the Nasdaq, Vertex remains a strong performer with potential for continued growth, especially with its promising pipeline.

    MSN·
    US
    VRTX
    -1.25%
    MSN·
    US
    VRTX
    -1.25%

    Zacks Research Issues Negative Outlook for VRTX Earnings

    Zacks Research has lowered its Q2 2027 earnings per share estimates for Vertex Pharmaceuticals from $4.60 to $4.45. Despite this, Vertex reported strong Q3 earnings of $4.80 per share, surpassing the consensus estimate of $4.58. The company's revenue for the quarter was $3.08 billion, up 11% year-over-year. Various analysts have adjusted their price targets for Vertex, with ratings ranging from 'buy' to 'hold'. Vertex's stock is currently trading at $429.82, with a market cap of $109.05 billion.

    Market Beat·
    US
    VRTX
    -1.25%
    Market Beat·
    US
    VRTX
    -1.25%
    © 2025 Longbridge｜Disclaimer